Lobbying disclosures · Lobbying report
MRK: third_quarter 2026 lobbying report
340B Program. Issues related to drug pricing. General pharmaceutical issues. Pubic health issues. Issues related to MFN. Appropriations and budget legislation for FY27. Reconciliation. Issues related to supply chain and shortages. Issues on vaccine policy. PBM reform. FDA issues. IRA Implementation. Issues related to Medicare Part B and D. Issues related to Medicaid Drug Rebate Program (MDRP).
Follow MRK- Became public
- Oct 19, 2026, 8:30 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 7:09 AM EST
Why this is connected
Exact legal-name match: Merck & Co., Inc. (https://www.sec.gov/Archives/edgar/data/310158/).
Reported lobbying amounts
Income: $50,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/c02d910b-f645-44d1-bbe4-011cfda8aa3d/","filing_uuid":"c02d910b-f645-44d1-bbe4-011cfda8aa3d","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/c02d910b-f645-44d1-bbe4-011cfda8aa3d/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-10-19T08:30:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 New York Avenue, NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401103321,"url":"https://lda.gov/api/v1/registrants/401103321/","house_registrant_id":null,"name":"TODD STRATEGY GROUP","description":"​Government Affairs Consulting Firm.","address_1":"1201 New York Avenue, NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-352-7761","dt_updated":"2026-07-30T17:35:40.053965-04:00"},"client":{"id":205226,"url":"https://lda.gov/api/v1/clients/205226/","client_id":315,"name":"MERCK & CO., INC.","general_description":"Pharmaceutical Company.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"340B Program. Issues related to drug pricing. General pharmaceutical issues. Pubic health issues. Issues related to MFN. Appropriations and budget legislation for FY27. Reconciliation. Issues related to supply chain and shortages. Issues on vaccine policy. PBM reform. FDA issues. IRA Implementation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg","new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":"Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid","new":false},{"lobbyist":{"id":109746,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"UEHLECKE","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to Medicare Part B and D. Issues related to Medicaid Drug Rebate Program (MDRP).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":109746,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"UEHLECKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in MRK
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 2, 2026 · disclosed Nov 5, 2026 · Dependent
- Oct 7, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
Sold (partial) Merck & Co. MRK
$1K–$15K · Traded Sep 24, 2026 · disclosed Oct 7, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 9, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Sep 9, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
$15K–$50K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 30, 2026$1K–$15K
Rep. Keith Self (R-TX-3)
$1K–$15K · Traded Jan 10, 2025 · disclosed Jun 30, 2026 · filed 536 days later
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.